25T4-NBOMe

In the world of 25T4-NBOMe, there has always been significant and varied interest. Whether we are talking about a person's life, a current topic, or a historical event, 25T4-NBOMe has captured the imagination of many people over the years. In this article, we will explore 25T4-NBOMe in depth and examine its impacts, relevance, and how it has influenced different aspects of society. From its origin to its evolution today, 25T4-NBOMe has left an indelible mark on the world, and it is essential to understand its importance to appreciate its meaning in our daily lives.

25T4-NBOMe
Clinical data
Other names2C-T-4-NBOMe; NBOMe-2C-T-4
Drug classSerotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • 2-(2,5-dimethoxy-4-propan-2-ylsulfanylphenyl)-N-ethanamine
CAS Number
PubChem CID
Chemical and physical data
FormulaC21H29NO3S
Molar mass375.53 g·mol−1
3D model (JSmol)
  • CC(C)SC1=C(C=C(C(=C1)OC)CCNCC2=CC=CC=C2OC)OC
  • InChI=1S/C21H29NO3S/c1-15(2)26-21-13-19(24-4)16(12-20(21)25-5)10-11-22-14-17-8-6-7-9-18(17)23-3/h6-9,12-13,15,22H,10-11,14H2,1-5H3
  • Key:BOWHVFJVXBVJCU-UHFFFAOYSA-N

25T4-NBOMe is a serotonergic psychedelic of the 25-NB (NBOMe) family.[1][2][3][4] It is the NBOMe analogue of 2C-T-4.[1][2][3][4] The drug acts as a highly potent and selective agonist of the serotonin 5-HT2 receptors.[5][6] Its reported actve dose range has been described as 150 to 1,200 μg, with a typical dose estimate of 500 μg.[7] 25T4-NBOMe was first described in the scientific literature by at least 2012.[8]

See also

References

  1. ^ a b Gil-Martins E, Barbosa DJ, Borges F, Remião F, Silva R (June 2025). "Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?". Toxicol Rep. 14: 101890. Bibcode:2025ToxR...1401890G. doi:10.1016/j.toxrep.2025.101890. PMC 11762925. PMID 39867514.
  2. ^ a b Zawilska JB, Kacela M, Adamowicz P (2020). "NBOMes-Highly Potent and Toxic Alternatives of LSD". Front Neurosci. 14: 78. doi:10.3389/fnins.2020.00078. PMC 7054380. PMID 32174803.
  3. ^ a b Kyriakou C, Marinelli E, Frati P, Santurro A, Afxentiou M, Zaami S, Busardo FP (September 2015). "NBOMe: new potent hallucinogens--pharmacology, analytical methods, toxicities, fatalities: a review" (PDF). Eur Rev Med Pharmacol Sci. 19 (17): 3270–3281. PMID 26400534.
  4. ^ a b Awuchi, Chinaza Godswill; Aja, Maduabuchi Patrick; Mitaki, Nancy Bonareri; Morya, Sonia; Amagwula, Ikechukwu O.; Echeta, Chinelo Kate; Igwe, Victory S. (2 February 2023). "New Psychoactive Substances: Major Groups, Laboratory Testing Challenges, Public Health Concerns, and Community-Based Solutions". Journal of Chemistry. 2023: 1–36. doi:10.1155/2023/5852315. ISSN 2090-9071. S2CID 256567458.
  5. ^ Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)" (PDF). Neuropharmacology. 99: 546–553. doi:10.1016/j.neuropharm.2015.08.034. PMID 26318099.
  6. ^ Åstrand A, Guerrieri D, Vikingsson S, Kronstrand R, Green H (December 2020). "In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors-On-target receptor potency and efficacy, and off-target effects". Forensic Sci Int. 317: 110553. doi:10.1016/j.forsciint.2020.110553. PMID 33160102.
  7. ^ Luethi D, Liechti ME (October 2018). "Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics". Int J Neuropsychopharmacol. 21 (10): 926–931. doi:10.1093/ijnp/pyy047. PMC 6165951. PMID 29850881.
  8. ^ Casale, J. F., & Hays, P. A. (2012). Characterization of eleven 2, 5-dimethoxy-N-(2-methoxybenzyl) phenethylamine (NBOMe) derivatives and differentiation from their 3-and 4-methoxybenzyl analogues—part I. Microgram Journal, 9(2), 84–109. https://www.dea.gov/sites/default/files/pr/microgram-journals/2012/mj9_84-109.pdf



Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.